Trial site
Unidade Local De Saude De Tras-Os-Montes E Alto Douro E.P.E.
Vila Real, 5000-508, PortugalNot linked to an institution yet
- 15running trials
- 3closed trials
The trials here
What the 18 trials at this site are about, from their registry records.
- Phase
- Phase 316 trials
- Phase 21 trial
- Phase 41 trial
- Status
- Recruiting9 trials
- Active, not recruiting4 trials
- Completed3 trials
- Not yet recruiting2 trials
- Lead sponsor
- AstraZeneca2 trials
- Xenon Pharmaceuticals Inc.2 trials
- Alnylam Pharmaceuticals1 trial
- Astellas Pharma Global Development, Inc.1 trial
- European Myeloma Network B.V.1 trial
- and 11 more
Running trials
Recruiting
A Phase 3 Study Comparing Ramantamig plus Daratumumab Versus DVRd or DRd in Participants With NDMM for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
2026-526654-14-01· Phase 3· Janssen Cilag International· Source
Recruiting
A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer
NCT07673887· Phase 3· Astellas Pharma Global Development, Inc.· Source
Recruiting
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
NCT07085767· Phase 3· Olema Pharmaceuticals, Inc.· Source
Recruiting
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
NCT07052903· Phase 3· Alnylam Pharmaceuticals· Source
Recruiting
Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype
NCT06486883· Phase 2· MedSIR· Source
Recruiting
Multi-center Trial of Ferric Derisomaltose Versus no Intravenous Iron in Iron-deficient Subjects With Symptomatic Chronic Heart Failure
NCT06929806· Phase 3· Pharmacosmos A/S· Source
Recruiting
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
NCT06532006· Phase 3· Shanghai Henlius Biotech· Source
Active, not recruiting
A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)
NCT06525220· Phase 3· Genmab· Source
Recruiting
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
NCT06380751· Phase 3· AstraZeneca· Source
Active, not recruiting
MAGNETICAL - MAGNetic resonance Evaluation of Tafamidis Impact in Cardiac AmyLoidosis
2024-518708-29-00· Phase 4· Unidade Local De Saude De Tras-Os-Montes E Alto Douro E.P.E.· Source
Recruiting
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
NCT06051617· Phase 3· Gilead Sciences· Source
Recruiting
A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis
NCT06016842· Phase 3· Ipsen· Source
Enrolling by invitation
An Open-label Study of XEN1101 in Epilepsy
NCT05718817· Phase 3· Xenon Pharmaceuticals Inc.· Source
Active, not recruiting
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
NCT05243797· Phase 3· European Myeloma Network B.V.· Source
Active, not recruiting
Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC
NCT05301842· Phase 3· AstraZeneca· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error